NCT06329206View on ClinicalTrials.gov

A Phase Ia/Ib Study of GH2616 Tablet in Subjects With Advanced Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

March 20, 2024

Primary Completion Date

April 25, 2026

Study Completion Date

September 1, 2026

Conditions
Advanced Solid Tumors
Interventions
DRUG

GH2616 Tablets

GH2616 tablets will be given orally

Trial Locations (1)

Unknown

RECRUITING

Zhejiang Cancer Hospital, Zhejiang

All Listed Sponsors
collaborator

Zhejiang Cancer Hospital

OTHER

collaborator

Henan Cancer Hospital

OTHER_GOV

collaborator

Hubei Cancer Hospital

OTHER

collaborator

The First Affiliated Hospital of Zhengzhou University

OTHER

lead

Suzhou Genhouse Bio Co., Ltd.

OTHER